- Current report filing (8-K)
July 09 2012 - 1:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported)
July 2, 2012
ACCELR8
TECHNOLOGY CORPORATION
(Exact name of registrant as specified in
its charter)
COLORADO
(State or other jurisdiction of incorporation)
0-11485
|
84-1072256
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
7000 North Broadway, Building 3-307, Denver, CO
|
80221
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
(303)
863-8808
(Registrant’s telephone number, including
area code)
Not
applicable
(Former name or former address, if changed
since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 2, 2012, the board of directors (the “Board”)
of Accelr8 Technology Corporation (the “Company”) appointed Matthew W. Strobeck, Ph.D., as a member of the Board, effective
immediately. On the same date, the Board also appointed Dr. Strobeck and Jack Schuler as members of the Company’s Audit Committee,
effective immediately.
Dr. Strobeck, 39, currently serves as a director of Metabolix,
Inc. (NASDAQ: MBLX), an innovation-driven bioscience company focused on delivering sustainable solutions to the plastics, chemicals
and energy industries, and Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company focused on acquiring, developing
and commercializing proprietary products that address the needs of patients treated by physician specialists.
He
was a Partner and Member of the Management Committee and Advisory Board of Westfield Capital Management from 2008 until 2011, having
served as a member of the investment team, specializing in healthcare and life sciences, from May 2003 to June 2008. Dr. Strobeck
was a fellow in the Department of Biology at MIT from December 2001 to June 2002. Dr. Strobeck recently joined the Board of
Directors of Santarus, Inc. Dr. Strobeck received his B.S. from St. Lawrence University, a Ph.D. from the University
of Cincinnati, a S.M. from Harvard University/MIT Health Sciences Technology Program, and a S.M. from the MIT Sloan School of Management.
SIGNATURES
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: July 9, 2012
|
ACCELR8 TECHNOLOGY CORPORATION
(Registrant)
/s/ Lawrence Mehren
Lawrence Mehren
Chief Executive Officer
|
|
|
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jul 2023 to Jul 2024